ASH 2025: J&J’s Tecvayli + Darzalex set to redefine early relapsed MM
At the American Society of Hematology (ASH) Annual Meeting 2025, held in Orlando, Florida, from 6 to 9 December, updated…
Oncology
-
-
Roche posts second Phase III win for oral SERD
Roche’s oral selective oestrogen receptor degrader (SERD) has reduced the risk of invasive disease recurrence or death by 30% in…
-
ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM
At the American Society of Hematology (ASH) Annual Meeting 2025, held in Orlando, Florida and online from 7 to 10…
-
Redefining clinical trials in oncology and rare diseases across the Europe
Later this month, experts from the pharmaceutical and biotechnology industry and patient advocacy space will gather in Munich, Germany, to…
-
Nuvalent aiming for approval on pivotal trial data for NSCLC candidate
Nuvalent’s stock price oscillated after it’s investigational ALK-selective inhibitor showed promise in patients with advanced ALK-positive non-small cell lung cancer…
-
Roche reports positive Phase III data of giredestrant for breast cancer
Roche has reported encouraging outcomes from its Phase III lidERA Breast Cancer trial of oral giredestrant as an adjuvant endocrine…
-
Cogent’s stock soars on Phase III gastrointestinal cancer data
Cogent Biosciences' stock has soared after its lead asset, bezuclastinib plus sunitinib, outperformed sunitinib alone in a pivotal gastrointestinal cancer…
-
Aulos looks to Phase III for IL-2 mAb in NSCLC and melanoma
Aulos Bioscience’s cancer therapy, imneskibart, could enter a registrational study either in melanoma, non-small cell lung cancer (NSCLC) or both,…
-
Intensity Therapeutics stock up nearly 400% on solid tumour data
Intensity Therapeutics’ stock has risen nearly 400% after its oncology candidate showed high overall survival (OS) and disease control. In…
-
Proactive strategy needed to ensure Project Optimus compliance
Sponsors should ensure dose optimisation is a part of early trial planning for oncology trials as the US Food and…
